Filing in this field is concentrated at the top: the five most active assignees together account for 32.5% of the 366 records in scope, and the ten most active account for 47.0%. That leaves a long tail of single- or few-filing entrants outside the ranked leaders. Anyone entering this space should expect to run freedom-to-operate checks primarily against a small number of established filers, since they hold a disproportionate share of the filed art relative to their number.

Filings peaked in 2021 at 12 for the year and fell to 8 by 2024, a -33% change over that three-year span — the most recent period that can be treated as complete. Data for 2025 and 2026 is still incomplete because publication typically lags filing by around 18 months, so those later years understate true filing activity and should not be read as a continued decline. A fair reading is that filing has eased off its 2021 peak but has not necessarily stopped.

C12N (microorganisms and genetic engineering) and C12P (fermentation and enzymatic synthesis) are the two dominant classes, appearing on 64.5% and 62.8% of the 366 records in scope respectively — meaning most filings claim either the host organism or the production process itself. C12M, covering bioreactors and enzyme apparatus, appears on 27.3% of records, showing that hardware and vessel-level claims are a secondary but still substantial layer. Because a single record can carry multiple IPC codes, these shares add up to more than 100% and should not be read as mutually exclusive categories.

US20090181433A1, filed by Genencor International in 2009, covers methods for producing end-products from carbon substrates such as starch and cellulose through bioconversion, with preferred embodiments that avoid requiring conventional gelatinization or liquefaction of the substrate. It is most relevant to anyone designing a bioconversion process around biomass feedstocks that skips those pretreatment steps. It sits inside the dense C12P cluster that covers 62.8% of records in this field, so it should be treated as one of several records to clear on a freedom-to-operate review, not the sole barrier.

The thinnest classes in this dataset are A01N (biocide and agrochemical applications, 6.0% of records), A61P (therapeutic activity, 6.3%) and C07H (sugar and nucleic-acid chemistry, 7.1%) — all far below the C12N/C12P fermentation core. These adjacent-use branches are technically connected to the same enzyme systems but are claimed far less densely, which suggests room for claims that tie a specific fermentation-derived enzyme to one of these end-uses rather than claiming the organism or process alone. Geographic filing is also uneven: India carries only 18 of the 366 records against 79 in the United States, pointing to a thinner prior-art base in some jurisdictions.